{"version":"1.0","type":"link","title":"Cost effectiveness analysis of immunotherapy regimens currently approved in advanced or recurrent endometrial cancer: An analysis of the NRG-GY 018, RUBY, and DUO-E trials.","author_name":"Francoeur AA 외","author_url":"https://prs-insight.online/author/Francoeur%20AA","provider_name":"PRSinsight","provider_url":"https://prs-insight.online","thumbnail_url":"https://prs-insight.online/og/paper/167236","thumbnail_width":1200,"thumbnail_height":630}